Dynamic Changes in Circulating Tumor DNA in Hepatocellular Carcinoma Patients Reveal Its Potential as a Non-Invasive Biomarker

Dynamic Changes in Circulating Tumor DNA in Hepatocellular Carcinoma Patients Reveal Its Potential as a Non-Invasive Biomarker

2024.09.04
A recent clinical study conducted by Dr. Jean-Charles Nault and his team at the Cordeliers Research Center of Sorbonne University, France, was published in Gut journal. This study reveals the dynamic changes in circulating tumor DNA (ctDNA) in patients with hepatocellular carcinoma (HCC) and its clinical significance. The findings provide new perspectives and tools for the clinical management of HCC, highlighting the potential of ctDNA monitoring as an important adjunct in the diagnosis and treatment of HCC.
Newly Released! IDSA 2024 Guidelines for Treating Resistant Gram-Negative Bacterial Infections

Newly Released! IDSA 2024 Guidelines for Treating Resistant Gram-Negative Bacterial Infections

2024.09.04
As antimicrobial resistance (AMR) continues to be a growing global public health challenge, treating infections caused by resistant bacteria has become increasingly difficult. Recently, the Infectious Diseases Society of America (IDSA) released the "IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections," providing clinicians with valuable treatment recommendations. This document primarily addresses infections caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E), AmpC beta-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Enterobacterales (CRE), difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia, offering specific and comprehensive treatment advice. Infectious Disease Frontier has translated and summarized the relevant recommendations from the document for reference by our readers.
Dr. Steven Narod: Bilateral Mastectomy and Breast Cancer Mortality—A Rethink of Clinical Guidelines

Dr. Steven Narod: Bilateral Mastectomy and Breast Cancer Mortality—A Rethink of Clinical Guidelines

2024.09.04
In recent years, bilateral mastectomy, as a surgical approach to prevent contralateral breast cancer, has gained a certain degree of attention and application. However, there is still controversy regarding the actual effectiveness of bilateral mastectomy in preventing breast cancer mortality. Recently, Dr. Steven Narod from the Dalla Lana School of Public Health published a research paper titled "Bilateral Mastectomy and Breast Cancer Mortality" in JAMA Oncology. "Oncology Frontier" specially invited Dr. Steven Narod to share his latest research findings, hoping to provide more thoughts and guidance for the prevention, diagnosis, and treatment of breast cancer.
International Perspective丨Weighing the Risks of Chemotherapy: Is Chemotherapy Necessary for Adjuvant and Stage IV NSCLC Treatment?

International Perspective丨Weighing the Risks of Chemotherapy: Is Chemotherapy Necessary for Adjuvant and Stage IV NSCLC Treatment?

2024.09.03
The necessity of adding chemotherapy to postoperative adjuvant treatment and in Stage IV non-small cell lung cancer (NSCLC) remains a topic of debate. In this article, Dr. Mark G. Kris from Memorial Sloan Kettering Cancer Center analyzes the value of chemotherapy in the adjuvant treatment of early-stage NSCLC with EGFR and ALK mutations, as well as in the treatment of advanced lung cancer.
International Perspective丨What Challenges Does Immunotherapy Face in Early-Stage NSCLC?

International Perspective丨What Challenges Does Immunotherapy Face in Early-Stage NSCLC?

2024.09.03
The successes of immunotherapy and targeted therapy in metastatic non-small cell lung cancer (NSCLC) have raised hopes for implementing these therapies in earlier stages of the disease. Recent trial results indicate that neoadjuvant, adjuvant, and perioperative immunotherapy may improve the cure rates of early-stage NSCLC. While early diagnosis of patients could make immunotherapy a significant option for early-stage NSCLC, identifying reliable biomarkers remains a challenge.
Lung Cancer Frontline丨Dr. Cho Discusses the Impact of the CHRYSALIS-2 Cohort C Study on the Treatment of Atypical EGFR-Mutant Lung Cancer

Lung Cancer Frontline丨Dr. Cho Discusses the Impact of the CHRYSALIS-2 Cohort C Study on the Treatment of Atypical EGFR-Mutant Lung Cancer

2024.09.03
The CHRYSALIS-2 study (NCT04077463) Cohort C investigated the combination of amivantamab and lazertinib for the treatment of patients with atypical EGFR-mutant non-small cell lung cancer (NSCLC). The study enrolled patients with various EGFR mutations who were either treatment-naive or had received limited prior treatment. The results demonstrated that the amivantamab+lazertinib combination showed promising antitumor activity, particularly in treatment-naive patients. The overall response rate was 51% (95% CI: 41%-61%), with a response rate of 55% (95% CI: 40%-69%) in treatment-naive patients. In this subgroup, the median progression-free survival (PFS) for the amivantamab+lazertinib combination was 19.5 months (95% CI: 11.0-not estimable). Overall, these findings suggest that amivantamab+lazertinib has potential as a new treatment option for patients with advanced NSCLC carrying atypical EGFR mutations. Principal investigator Dr. Byoung Chul Cho from Yonsei Cancer Center in Korea discussed the results of this study in an international media interview.
International Lung Cancer Academic Conference | Dr. Chunxue Bai: Lung Cancer Screening and Management in the Metaverse Era

International Lung Cancer Academic Conference | Dr. Chunxue Bai: Lung Cancer Screening and Management in the Metaverse Era

2024.09.03
In 2022, Dr. Chunxue Bai from Fudan University Shanghai Cancer Center, introduced the concept of "Metaverse Medicine," aiming to leverage metaverse technology to revolutionize disease prevention and treatment. At the 2024 International Lung Cancer Academic Conference, Professor Bai presented a report titled "Lung Cancer Screening and Management in the Metaverse Era." This article provides a summary of the main points of his report.
Balancing Standardization and Innovation: Dr. Jin Li Shares Conference Highlights and the Future of AI in Clinical Research

Balancing Standardization and Innovation: Dr. Jin Li Shares Conference Highlights and the Future of AI in Clinical Research

2024.09.03
The "2024 CSCO Digestive Tract Tumor Standardized Treatment Workshop," co-hosted by the Chinese Society of Clinical Oncology, Beijing Xisike Clinical Oncology Research Foundation, and Hangzhou Oriental Clinical Oncology Research Center, was held in Shanghai from August 17-18, 2024. This workshop featured diverse learning methods, including lectures, discussions, and live surgical demonstrations, aimed at improving the standardized treatment of digestive tract tumors, reducing regional disparities, and disseminating new advancements and concepts. Oncology Frontier interviewed Dr. Jin Li, President of Shanghai GoBroad Cancer Hospital China Pharmaceutical University, Chairman of the CSCO Foundation, and Chairman of the CSCO Gastric Cancer Expert Committee, to discuss the highlights and significance of this workshop, as well as the potential and future of artificial intelligence in clinical research.
In-Depth Analysis of UTUC MDT Diagnosis, Radiotherapy, and Translational Development, Pioneering the Path Forward with CUDA-UTUC

In-Depth Analysis of UTUC MDT Diagnosis, Radiotherapy, and Translational Development, Pioneering the Path Forward with CUDA-UTUC

2024.09.03
From August 8 to 11, 2024, the Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) was held in Xi'an. The conference was hosted by the Chinese Medical Association and the CUDA Urological Surgeons Branch, with the Air Force Medical University Xijing Hospital as the organizer and the Shaanxi Provincial Medical Association Urological Surgeons Branch as a co-organizer. Under the theme of "Healthy China, Urology First," the conference gathered many of the latest achievements in urology. At the event, Urology Frontier invited Dr. Xuesong Li, Dr. Qi Tang, and Dr. Xiaoying Li from Peking University First Hospital for an in-depth discussion on the current state of non-invasive detection, radiotherapy, and translational medicine for upper tract urothelial carcinoma (UTUC). They also shared their experiences in building subspecialties for UTUC and outlined the direction in which CUDA-UTUC is leading the field.